首页> 外文期刊>Drug development and industrial pharmacy >Formulation and ex vivo–in vivo evaluation of pH-triggered brimonidine tartrate in situ gel for the glaucoma treatment using application of 32 factorial design
【24h】

Formulation and ex vivo–in vivo evaluation of pH-triggered brimonidine tartrate in situ gel for the glaucoma treatment using application of 32 factorial design

机译:使用32种造型设计,使用32种造型设计的制定凝胶胰蛋白酶凝胶的制剂和离体的体内评价

获取原文
获取原文并翻译 | 示例
       

摘要

Context: Short residence time, poor bioavailability and poor permeability are the major problems for conventional eye drops treatment. Objective: The aim of this article is to develop, optimize and ex vivo–in vivo investigation of brimonidine tartrate in situ gel as compared to marketed eye drops for the treatment of glaucoma. Materials and methods: The effect of independent variables, namely concentrations of polymers, on various dependent variables like viscosity at physiological pH and in vitro drug release were studied by using 32 factorial design. Further the optimized formulation was characterized for ex vivo and in vivo study. Results and discussion: Experimental data demonstrated that optimized in situ gel formulation (F8) showed in vitro–ex vivo sustained release profile with polymer composites carbopol 974P and HPMC K4M. After 5 h of ex vivo transcorneal permeation study, the amount recovered from the corneal surface on the donor chamber 12.40% (124 ug) and the amount collected from the receptor chamber 76.8% (760 ug) of the initial dose 1 mg. The total amount recovered from the permeation experiment was 89.2%. Bioadhesive carbopol 974P and viscosity HPMC K4M composites optimized formulation (F 8) produce greater influence on the duration of drug action and improved intraocular pressure reduction activity as compared to marketed eye drop solution in in vivo study. Conclusion: The developed in situ gelling system as a promising ophthalmic formulation to prolong the drug lowering effect on the intraocular pressure.
机译:背景信息:短暂停留时间,生物利用度不佳,渗透率差是常规眼药水处理的主要问题。目的:本文的目的是发展,优化和离体体内对原位凝胶的硫代瓜啶酒石酸盐的研究,与营销眼药水用于治疗青光眼。材料和方法:通过使用32个因素设计研究了独立变量,即聚合物的浓度,即聚合物的浓度,例如生理pH值和体外药物释放的各种依赖性变量。此外,优化的制剂的特征在于例如离体和体内研究。结果与讨论:实验数据证明,原位凝胶配方(F8)优化,其在体外 - 离体持续释放曲线中显示,具有聚合物复合材料Carbopol 974P和HPMC K4M。在离体转基型渗透研究5小时后,从供体室的角膜表面回收的量12.40%(124ug)和从初始剂量1mg的受体室76.8%(760ug)收集的量。从渗透实验中回收的总量为89.2%。生物粘附性Carbopol 974P和粘度HPMC K4M复合材料优化配方(F 8)对药物作用的持续时间产生更大的影响,并与体内研究中的市场滴眼液溶液相比,改善的眼压降低活性。结论:原位胶凝系统开发为有前途的眼科配方,延长药物降低对眼压的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号